Galapagos identifies possible new osteoarthritis drug

BRUSSELS Tue Jul 24, 2012 1:54am EDT

BRUSSELS (Reuters) - Belgian drug developer Galapagos is in line for an undisclosed milestone payment after identifying a possible oral treatment for osteoarthritis as part of its collaboration with France's Servier, it said on Tuesday.

"This achievement also marks the third alliance with a different pharma partner in which Galapagos has identified a pre-clinical candidate," Onno van de Stolpe, Chief Executive Officer of Galapagos, said in a statement.

(Reporting By Ben Deighton)